MedTrace Logo

Chronic Consumption of Vinegar on Visceral Adiposity in Overweight Adults (VAnish)

NCT04706520 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-11-16

No results posted yet for this study

Summary

To assess, relative to a placebo, the effects of consuming 400 mL/day or 200 mL/day of a vinegar beverage providing either 1,500 mg/day of acetic acid (in two 200 mL doses daily) or 750 mg/day of acetic acid (in one 200 mL dose daily), respectively, for 12 weeks on VAT (MRI). Thus the 2 active comparator arms 400 mL and 200 mL of vinegar will be independently tested compared to placebo.

Conditions

  • Body Composition

Interventions

DIETARY_SUPPLEMENT

Study Beverage Consumption

All participants will follow the same intervention as the study staff is blinded in addition to the participant. Randomized participants will be asked to consume 2 bottles per day of a study beverage for 12 weeks. Compliance checks will occur remotely by having participants send photos of their bottles each day and weekly phone/video calls with intervention staff. Participants will be asked to keep their diet and activity level consistent throughout the 12 weeks.

Sponsors & Collaborators

  • Mizkan Holdings Co., Ltd.

    collaborator INDUSTRY

  • Pennington Biomedical Research Center

    lead OTHER

Principal Investigators

  • Frank J Greenway, MD · Pennington Biomedical Research Center

  • Shengping Yang, PhD · Pennington Biomedical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-10
Primary Completion
2021-11-04
Completion
2021-11-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04706520 on ClinicalTrials.gov